Table 3. Type-specific HPV clearance and TLR9 genotypes using two different definitions for clearance.
Significant associations are highlighted in bold.
| Genotype/species | Clearance definition 1* | Clearance definition 2† | ||||||
| Dominant model‡ | Recessive model§ | Dominant model‡ | Recessive model§ | |||||
| Events | HR | Events | HR | Events | HR | Events | HR | |
| HPV genotype | ||||||||
| 6/11 | 24 | 1.54 (0.79–2.99) | 3 | 1.46 (0.44–4.81) | 20 | 1.42 (0.72–2.78) | 2 | 3.41 (0.74–15.64) |
| 16 | 37 | 1.09 (0.71–1.69) | 5 | 1.27 (0.51–3.19) | 36 | 0.99 (0.63–1.55) | 5 | 1.31 (0.52–3.28) |
| 18 | 8 | 1.95 (0.82–4.63) | 0 | na | 5 | 1.47 (0.52–4.14) | 0 | na |
| 31 | 10 | 0.90 (0.39–2.09) | 0 | na | 8 | 1.07 (0.44–2.59) | 0 | na |
| 33 | 9 | 0.95 (0.34–2.65) | 1 | 0.55 (0.07–4.41) | 8 | 0.92 (0.32–2.63) | 1 | 0.46 (0.06–3.75) |
| 35 | 16 | 0.63 (0.28–1.44) | 1 | 1.37 (0.18–10.52) | 14 | 1.05 (0.41–2.71) | 1 | 5.41 (0.60–48.64) |
| 45 | 9 | 0.76 (0.33–1.78) | 3 | 0.62 (0.18–2.11) | 8 | 0.83 (0.34–1.99) | 3 | 0.85 (0.24–2.97) |
| 51 | 17 | 0.94 (0.49–1.80) | 3 | 5.26 (1.58–17.53) | 15 | 0.77 (0.38–1.56) | 3 | 6.70 (1.75–25.65) |
| 52 | 14 | 1.58 (0.75–3.34) | 2 | 1.68 (0.40–7.16) | 13 | 1.41 (0.69–2.89) | 2 | 2.74 (0.62–12.09) |
| 53 | 25 | 0.76 (0.33–1.78) | 3 | 0.62 (0.18–2.11) | 24 | 1.33 (0.76–2.34) | 1 | 0.71 (0.10–5.23) |
| 54 | 17 | 1.13 (0.55–2.317) | 1 | 1.12 (0.15–8.45) | 16 | 1.11 (0.53–2.31) | 1 | 1.78 (0.23–13.76) |
| 55 | 16 | 1.04 (0.50–2.17) | 3 | 0.72 (0.21–2.40) | 12 | 0.84 (0.34–2.10) | 2 | 0.47 (0.10–2.12) |
| 56 | 15 | 1.31 (0.57–3.02) | 1 | 2.09 (0.26–16.54) | 14 | 1.39 (0.58–3.35) | 1 | 10.78 (0.97–119.70) |
| 58 | 11 | 1.30 (1.70–229.99) | 1 | 19.79(1.70–230.0) | 11 | 1.56 (0.66–3.65) | 1 | 8.71 (0.92–82.98) |
| 59 | 10 | 0.57 (0.21–1.56) | 1 | 4.97 (0.34–72.82) | 8 | 0.32 (0.10–0.98) | 0 | na |
| 61 | 7 | 0.80 (0.30–2.15) | 4 | 1.17 (0.38–3.60) | 6 | 0.90 (0.32–2.54) | 3 | 0.90 (0.26–3.19) |
| 68 | 11 | 1.39 (0.58–3.38) | 3 | 1.21 (0.32–4.57) | 9 | 1.29 (0.49–3.40) | 3 | 1.37 (0.36–5.21) |
| 73 | 3 | 2.52 (0.64–9.88) | 0 | na | 3 | 2.67 (0.70–10.22) | 0 | na |
| 89 | 4 | … | 1 | 0.47 (0.03–6.42) | 3 | na | 1 | na |
| Any HPV | 158 | 0.98 (0.80–1.20) | 16 | 1.18 (0.71–1.94) | 133 | 0.93 (0.75–1.16) | 14 | 1.30 (0.76–2.22) |
| Alphapapillomavirus species || | ||||||||
| Species 3 | 48 | 1.11 (0.76–1.63) | 7 | 0.78 (0.36–1.68) | 40 | 0.96 (0.64–1.45) | 6 | 0.85 (0.37–1.96) |
| Species 7 | 44 | 0.91 (0.62–1.34) | 6 | 0.88 (0.38–2.01) | 34 | 0.80 (0.52–1.23) | 5 | 0.65 (0.26–1.63) |
| Species 9 | 74 | 0.99 (0.73–1.33) | 9 | 1.29 (0.66–2.52) | 69 | 1.09 (0.80–1.50) | 9 | 1.56 (0.79–3.06) |
| Species 10 | 38 | 1.37 (0.85–2.21) | 5 | 0.96 (0.39–2.41) | 31 | 1.16 (0.69–1.94) | 3 | 0.72 (0.22–2.38) |
na, not applicable.
*
Definition 1: One negative follow-up visit after an HPV-positive test.
†
Definition 2: Two negative follow-up visits after an HPV-negative test.
‡
Dominant model: mutant homozygote (CC)+heterozygote (TC) versus WT homozygote (TT).
§
Recessive model: WT homozygote (TT)+heterozygote (TC) versus mutant homozygote (CC).
||Species 3 (HPV61, -72, -62, -81, -83, -84 and -89); species 7 (HPV18, -39, -45, -59, -68 and -70); species 9 (HPV16, -31, -33, -35, -52, -58 and -67); species 10 (HPV6, -11, -44 and -55).